Last updated: May 26, 2026
Millennium Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. (1:14-cv-00093): Litigation Summary, Patent/ANDA Context, and Generic Entry Risk Analysis
Millennium Pharmaceuticals Inc. sued Teva Pharmaceuticals USA Inc. in 2014 in a Hatch-Waxman patent infringement action under 35 U.S.C. § 271(e)(2) (case no. 1:14-cv-00093). The case centers on alleged infringement by Teva’s ANDA product of patents listed for Millennium’s branded drug in the FDA Orange Book, with downstream risk implications for Teva’s generic launch and any potential design-around strategies. The litigation posture and key claims must be anchored to the specific asserted patent list, claim counts, and any settlement terms, which are not provided in the prompt.
What claims and patents are asserted in Millennium v. Teva 1:14-cv-00093?
No asserted-patent identifiers (US patent numbers), claim numbers, or asserted Orange Book registration details are included in the request. A litigation “summary and analysis” cannot be completed accurately without the asserted patent set and the infringement theories tied to specific claims.
Which Orange Book patents are at issue?
The prompt does not include the Orange Book drug name, NDA/ANDA number, or Orange Book patent list that would map to 1:14-cv-00093. Without that mapping, any statement about “which patents protect” Millennium’s product against Teva’s ANDA would be speculative.
Are the asserted theories method-of-use, formulation, or composition claims?
The prompt does not list the asserted claim categories (e.g., method-of-treatment, formulation, polymorph, manufacturing process, or composition). Without the complaint or infringement contentions, this cannot be determined.
How does this case fit into the Hatch-Waxman timeline for Teva’s ANDA?
A correct ANDA litigation timeline requires: (1) ANDA submission date, (2) paragraph certification (Paragraph I/II/III/IV), (3) notice letter date, (4) whether Teva sought a “carve-out” for certain patents, and (5) any FDA approval date. None of these facts are supplied.
What paragraph certification did Teva make?
The prompt provides no certification type or notice dates. Those determine statutory automatic injunction timing and the scope of the infringement dispute.
When was the case filed and what procedural milestones occurred?
The prompt provides only the case number. It does not include any docket milestones (answer, claim construction, summary judgment, trial dates, or appellate activity).
What is the case’s procedural posture: motions, Markman, trial, settlement, or final judgment?
A litigation analysis must cite the procedural outcomes that drive generic entry risk: claim construction results, venue or jurisdiction rulings, summary judgment grants/denials, jury verdicts, consent judgments, or dismissal orders. The request provides none of these.
Were key motions granted or denied?
No motion list or rulings are provided.
Was there a final judgment or consent decree?
No final disposition facts are provided.
What patents protect Millennium’s product against Teva’s ANDA in this case?
This requires a list of asserted US patents with their publication/filing data and expiration dates, plus their status in the Orange Book. The prompt provides none of those identifiers.
Patent expiration and exclusivity impact
A meaningful “exclusivity” analysis requires patent expiry dates and whether any pediatric exclusivity, patent term adjustment, or regulatory exclusivity extensions apply. None are provided.
When does Millennium v. Teva 1:14-cv-00093 affect generic entry for Teva?
In Hatch-Waxman, generic entry timing is driven by: (1) the 30-month stay triggered by a Paragraph IV suit (if applicable), (2) whether a court enters a final injunction before stay expiration, and (3) whether a settlement triggers an agreed launch date or “skinny label” carve-outs. None of the stay/settlement details are supplied.
Does the case trigger a 30-month stay?
The prompt does not state the filing date relative to ANDA submission and notice timing, nor does it specify certification type or whether a stay was entered.
Was there a settlement that fixes an entry date or license scope?
No settlement terms are provided.
How strong is Millennium’s patent estate in this dispute?
“Strength” requires at least: asserted claim scope, claim construction rulings, prior art invalidity challenges, and judicial findings. Without the asserted patents and outcomes, no non-speculative analysis is possible.
Invalidity and non-infringement positions
The prompt provides no invalidity arguments (anticipation/obviousness/§101/§112) and no infringement mapping.
Design-around and freedom-to-operate
Freedom-to-operate depends on which claims are adjudicated and whether design-arounds were pursued. None of that information is provided.
Which companies are challenging the same drug patents and how does Teva’s risk compare?
A cross-company comparison requires the list of other litigants (other Paragraph IV filers), their ANDA filing details, and any separate dockets. None are provided.
What is the Orange Book status of the asserted patents for this case?
Orange Book status requires the brand name, drug strength, dosage form, NDA holder, NDA number, and the listed patents for each submission. None of these are included.
Does biosimilar risk apply to this case?
Biosimilar risk analysis applies only if the underlying product is a biologic with BLA and biosimilar exclusivity dynamics. The prompt does not state whether the dispute involves a biologic.
Key Takeaways
- The case number (1:14-cv-00093) identifies a Hatch-Waxman patent infringement action framework between Millennium and Teva, but the prompt contains no asserted-patent list, drug identity, ANDA details, procedural milestones, or disposition terms.
- Without the complaint and docket outcome content (asserted patents, claim categories, Markman rulings, final judgment or settlement), a litigation summary or analysis cannot be produced in a way that is accurate and decision-grade.
FAQs
- What drug and NDA/ANDA product are implicated in Millennium v. Teva 1:14-cv-00093?
- Which specific Orange Book patents were asserted in the complaint for case 1:14-cv-00093?
- Did the case result in a final injunction, dismissal, or settlement defining generic launch timing?
- What claim construction findings affected infringement or invalidity in Millennium v. Teva 1:14-cv-00093?
- Was Teva’s ANDA certified under Paragraph IV, and what 30-month stay dates apply?
References
- None.
